Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5715)
All Articles published online
|
Publishing Process of This Article
|
Oct 10, 2015 (publication date) through Aug 31, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mologni L. Current and future treatment of anaplastic lymphoma kinase-rearranged cancer. World J Clin Oncol 2015; 6(5): 104-108 [PMID: 26468446 DOI: 10.5306/wjco.v6.i5.104] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v6/i5/104.htm |
| Number | Citing Articles |
| 1 |
Niloufar Javanmardi, Susanne Fransson, Anna Djos, Rose-Marie Sjöberg, Staffan Nilsson, Katarina Truvé, Per Kogner, Tommy Martinsson. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-018-37240-z
|
| 2 |
Federica Zito Marino, Giulio Rossi, Marco Montella, Gerardo Botti, Rossella De Cecio, Alessandro Morabito, Carmine La Manna, Andrea Ronchi, Mariacarolina Micheli, Giuseppe Salatiello, Pietro Micheli, Danilo Rocco, Marina Accardo, Renato Franco. Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. American Journal of Surgical Pathology 2020; 44(3): 378 doi: 10.1097/PAS.0000000000001400
|
| 3 |
Till‐Martin Theilen, Jan Soerensen, Konrad Bochennek, Martina Becker, Dirk Schwabe, Udo Rolle, Thomas Klingebiel, Thomas Lehrnbecher. Crizotinib in ALK+ inflammatory myofibroblastic tumors—Current experience and future perspectives. Pediatric Blood & Cancer 2018; 65(4) doi: 10.1002/pbc.26920
|
| 4 |
Candice C. Poon, John J. Kelly. Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non‐small cell lung cancer. International Journal of Cancer 2017; 140(9): 1945 doi: 10.1002/ijc.30533
|
| 5 |
Kalliopi Tsakiri, Vassiliki Kotoula, Sotirios Lakis, Judith Müller, Florentia Fostira, Mattheos Bobos, Prodromos Hytiroglou, George Fountzilas. Crizotinib Failure in a TPM4-ALK–Rearranged Inflammatory Myofibroblastic Tumor With an Emerging ALK Kinase Domain Mutation. JCO Precision Oncology 2017; (1): 1 doi: 10.1200/PO.17.00015
|
| 6 |
V. Pratap Reddy Gajulapalli, Juyong Lee, Insuk Sohn. Ligand-based pharmacophore modelling in search of novel anaplastic lymphoma kinase inhibitors. Results in Chemistry 2023; 5: 100752 doi: 10.1016/j.rechem.2022.100752
|
| 7 |
Fatemeh Nili, Vahid Soleimani, Niusha Nobari, Hana Saffar, Arghavan Etebarian. ALK Positive Anaplastic Large Cell Lymphoma of Oral Cavity: A Case Report. International Journal of Cancer Management 2019; (In Press) doi: 10.5812/ijcm.85749
|
| 8 |
Soumitra Tole, Laura Wheaton, Sarah Alexander. Pediatric Anaplastic Large Cell Lymphoma—A Review. Oncology & Hematology Review (US) 2018; 14(1): 21 doi: 10.17925/OHR.2018.14.1.21
|
| 9 |
Mojgan Djavaheri-Mergny, Sylvie Giuriato, Mario P. Tschan, Magali Humbert. Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma. Cells 2019; 8(2): 103 doi: 10.3390/cells8020103
|
| 10 |
Ailbhe C. O'Neill, Jyothi P. Jagannathan, Nikhil H. Ramaiya. Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists. Korean Journal of Radiology 2017; 18(1): 6 doi: 10.3348/kjr.2017.18.1.6
|
| 11 |
Julie Frentzel, Domenico Sorrentino, Sylvie Giuriato. Targeting Autophagy in ALK-Associated Cancers. Cancers 2017; 9(12): 161 doi: 10.3390/cancers9120161
|